Increased Focus on Xarelto Injuries
Xarelto (rivaroxaban) is one of the newest blood thinners on the market and is manufactured by Bayer and marketed by Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals, in the United States. The drug was approved in 2011.
One of the big “selling” points for Xarelto as opposed to Coumadin (warfarin) is that the patient taking Xarelto does not have to submit himself or herself to regular blood draws and dietary restrictions. What promoters (a/k/a J&J sales representatives) of Xarelto conveniently do not tell doctors and patients is that there is no commonly available antidote for a Xarelto overdose. Thus, should a patient’s Xarelto levels reach a toxic level, the patient has a good chance of bleeding to death. This is just another sad example of how the medical community is duped by the drug industry.
Xarelto levels are affected by a number of factors including advanced age, renal (kidney) function, extremes in body weight, and drug-drug interactions (aspirin, ibuprofen, nonsteroidal antiinflammatory drugs, and many other drugs commonly used by patients). Recently, Xarelto’s competition, Pradaxa, has been under similar scrutiny which has resulted in a number of lawsuits against its manufacturer, Boehringer Ingelheim Pharmaceuticals, Inc.
Xarelto may already be on the same hazardous path that Pradaxa has taken. In 2012, a number of deaths and serious bleeding events were attributed to Xarelto. In addition, while it is supposed to prevent blood clots, the Food and Drug Administration (FDA) has already received reports of dangerous blood clots in people taking the drug. Some injuries include death caused by uncontrolled bleeding, intestinal bleeding, rectal bleeding and brain hemorrhaging.
Claudine Q. Homolash, Esquire, founder of the CQH Firm, is a whistleblower, pharmaceutical injury and personal injury lawyer representing clients nationwide. She can be contacted at email@example.com or (844) 677-4276 or (215) 496-1012 for a free legal consultation.